Roivant Sciences (ROIV) Net Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Net Margin came in at 1737.12% in Q4 2024, up 269369.0% YoY from N/an in Q1 2024, and up 280.43% on a QoQ basis from 962.75% in Q3 2024.
Powered by 
Analysis
Roivant Sciences (ROIV) Net Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Net Margin data on file, last reported at 1737.12% in Q4 2024.
- Quarterly Net Margin rose 269369.0% year-over-year to 1737.12% in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 1256.56% (up 171034.0% YoY) and the FY2025 annual result came in at 1284.5%, up 224787.0% from the prior year.
- Net Margin improved to 1737.12% in Q4 2024, from 962.75% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1737.12% in Q4 2024 to a low of 8191.34% in Q2 2022.
- A 5-year average of 2026.85% and a median of 1516.12% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin slumped 688458 bps — and 2023, when it soared 667522 bps.
- Tracing ROIV's Net Margin over 5 years: stood at 4792.99% in 2020, then surged by 71 bps to 1373.78% in 2021, then slumped by 126 bps to 3110.55% in 2022, then surged by 69 bps to 956.57% in 2023, then soared by 282 bps to 1737.12% in 2024.
- The last three Net Margin figures came in at 1737.12% (Q4 2024), 962.75% (Q3 2024), and 1115.06% (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | -20,152.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20,152.98% |
| Dec 31, 2025 | -13,129.81% |
| Sep 30, 2025 | -10,569.00% |
| Jun 30, 2025 | -12,622.63% |
| Dec 31, 2024 | -371.38% |
| Sep 30, 2024 | -6,255.28% |
| Jun 30, 2024 | 719.52% |
| Dec 31, 2023 | 20,675.56% |
| Sep 30, 2023 | -9,076.70% |
| Jun 30, 2023 | -1,516.12% |
| Dec 31, 2022 | -3,110.55% |
| Sep 30, 2022 | -2,520.71% |
| Jun 30, 2022 | -8,191.34% |
| Dec 31, 2021 | -1,373.78% |
| Sep 30, 2021 | -1,613.21% |
| Jun 30, 2021 | -1,306.76% |
| Dec 31, 2020 | -4,792.99% |
| Sep 30, 2020 | -4,043.69% |
| Jun 30, 2020 | -506.15% |